|
|
NEW ON THE MARKET
|
|
Oral factor Xa inhibitor rivaroxaban (XARELTO) for prophylaxis of thromboembolism
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Anticholinergic drug tiotropium (SPIRIVA) for COLD - results from UPLIFT- study
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Oral human rotavirus vaccine: what is the benefit of ROTARIX and ROTATEQ?
Early diagnosis of diseases: is screening with the DIAPAT-Health-check reasonable?
|
|
|
IN BRIEF
|
|
Do not presribe: oral hypoglycemic agent rosiglitazone (AVANDIA)
|
|
St John's wort (e.g. JARSIN): effective as antidepressant only in German speaking countries?
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Toxic epidermal necrolysis due to COX-2-inhibitor etoricoxib (ARCOXIA)
|
|
|
SIDE EFFECTS
|
|
Finally: cannabinoid receptor antagonist rimonabant (ACOMPLIA) off market
|
|